Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bello

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 1, 2022
Development of novel montmorillonite-based sustained release system for oral bromopride deliveryMurilo L Bello, Arídio M Junior, Caroline A Freitas, et al.
Journal of Atherosclerosis and Thrombosis|June 5, 2010
Antiplatelet activity and structure-activity relationship study of Pyrazolopyridine Derivatives as potential series for treating thrombotic diseasesR B Geraldo, M L Bello, L R S Dias, et al.
Neurology|December 24, 2010
SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophyE Pegoraro, E P Hoffman, L Piva, et al.
British Journal of Haematology|August 29, 2012
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 casesCarlos Montalbán, Víctor Abraira, Luca Arcaini, et al.
Blood|October 2, 2004
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseWalter Fiedler, Hubert Serve, Hartmut Döhner, et al.
Bioorganic Chemistry|September 1, 2021
Synthesis and in vitro and in silico studies of 1H- and 2H-1,2,3-triazoles as antichagasic agentsThais B Silva, Kathya N K Ji, Fernanda Petzold Pauli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaRobert J Motzer, M Dror Michaelson, Bruce G Redman, et al.
Lancet (London, England)|October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialGeorge D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
Minerva Medica|September 21, 2020
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectivesAdrián Mosquera Orgueira, Laura Bao Pérez, Alicia Mosquera Torre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 1, 2022
Development of novel montmorillonite-based sustained release system for oral bromopride deliveryMurilo L Bello, Arídio M Junior, Caroline A Freitas, et al.
Journal of Atherosclerosis and Thrombosis|June 5, 2010
Antiplatelet activity and structure-activity relationship study of Pyrazolopyridine Derivatives as potential series for treating thrombotic diseasesR B Geraldo, M L Bello, L R S Dias, et al.
Neurology|December 24, 2010
SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophyE Pegoraro, E P Hoffman, L Piva, et al.
British Journal of Haematology|August 29, 2012
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 casesCarlos Montalbán, Víctor Abraira, Luca Arcaini, et al.
Blood|October 2, 2004
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseWalter Fiedler, Hubert Serve, Hartmut Döhner, et al.
Bioorganic Chemistry|September 1, 2021
Synthesis and in vitro and in silico studies of 1H- and 2H-1,2,3-triazoles as antichagasic agentsThais B Silva, Kathya N K Ji, Fernanda Petzold Pauli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaRobert J Motzer, M Dror Michaelson, Bruce G Redman, et al.
Lancet (London, England)|October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialGeorge D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
Minerva Medica|September 21, 2020
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectivesAdrián Mosquera Orgueira, Laura Bao Pérez, Alicia Mosquera Torre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Pageof 18